Abstract 84P
Background
Macrophages represent the main infiltrating immune subset in most cancer types and tumor-associated macrophages (TAMs) sustain tumor growth, promote invasion and mediate immune suppression. Interestingly, a population of lipid-loaded macrophages has been recently identified in prostate cancer, colon cancer and melanoma. However, the mechanisms that drive lipid accumulation in macrophages and the functional impact of lipid-loading still need to be uncovered.
Methods
We profiled the cancer immune infiltrate in a murine model of melanoma and we performed bulk RNA sequencing of lipid-loaded macrophages to investigate pathways involved in lipid accumulation. We applied in vitro assays to dissect the interplay between macrophages and melanoma cells and we took advantage of immunofluorescence analysis to study the mechanisms responsible for lipid accumulation in tumor-conditioned macrophages.
Results
We confirmed that lipid accumulation is a feature of TAMs in melanoma and we observed that lipid-loaded macrophages express markers of immunosuppression, including arginase and PD-L1. Importantly, the abundance of lipid-loaded macrophages correlates with tumor size, suggesting their support to tumor progression. In vitro, cancer cells shift the polarization of macrophages toward a pro-tumoral state and augment their capability to accumulate lipid droplets when triggered with lipid species. In addition, autophagic flux resulted impaired in macrophages exposed to tumor cells, suggesting defective autophagy as a potential mechanism responsible for lipid accumulation. In the end, we observed that transcription factor EB (TFEB) is deregulated in tumor-conditioned macrophages, indicating a role of TFEB in promoting autophagy deficiency and lipid accumulation in TAMs.
Conclusions
Here we show that TAMs in melanoma accumulate lipids and acquire pro-tumorigenic and immunosuppressive features. Additionally, the inactivation of transcription factor EB promotes a defective autophagic machinery that could be relevant in lipid accumulation in TAMs. In this context, we believe that TFEB activation may prevent lipid accumulation thus potentially improving efficacy of current available immunotherapies and therefore representing a promising opportunity for cancer therapy.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Fondazione AIRC per la Ricerca sul Cancro.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Identification of proteins associated with mRNA processing and maturation by quantitative proteomic analysis in Indian cervical cancer patients
Presenter: Amrita Mukherjee
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract